Venous thromboembolism
Drug research and approvals for venous thromboembolism: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 21, 2026, 122 studies of venous thromboembolism are recruiting on ClinicalTrials.gov, Health Canada has authorized 32 drug trials for it since 2013, and the EU has 9 authorised medicines for it.
- Recruiting worldwide: 122
- Trials authorized in Canada: 32
- FDA orphan approvals: 0
- EU medicines: 9
- Aspirin vs. Rivaroxaban for Thromboprophylaxis in Multiple MyelomaNCT07907211 · Phase 4 · Chen Lijuan · starts Feb 1, 2024
- Danang Cerebral Venous Thrombosis RegistryNCT07890675 · Not reported · Da Nang Hospital · starts Oct 9, 2025
- Comparison of DOACs and LMWH for Thromboprophylaxis After Total Knee ArthroplastyNCT07869615 · Not applicable · Military Hospital of Tunis · starts Sep 15, 2026
- TRiP-cast Score Validation and Evaluation of Adherence to Preventive Anticoagulant Treatment in Patients With Lower…NCT07863115 · Not reported · University of Monastir · starts Sep 1, 2025
- Mobilisation After Endovascular Stroke TreatmentNCT07860333 · Not reported · Karolinska Institutet · starts May 7, 2026
- Circadian Variation of Anti-Factor Xa in Hospitalized Trauma PatientsNCT07856641 · Not reported · The University of Texas Health Science Center, Houston · starts Aug 26, 2026
- Pulmonary Embolism Registry From Short-Term Emergency to Long-Term Follow-Up and SurveillanceNCT07855679 · Not reported · Azienda Ospedaliero-Universitaria Careggi · starts Jun 19, 2026
- Vortosiran for VTE PreventionNCT07850453 · Phase 2 · Ribocure Pharmaceuticals AB · starts Nov 4, 2026
- Rivaroxaban vs Enoxaparin After Cesarean Section: Laboratory Thromboprophylaxis OutcomesNCT07820670 · Not applicable · Wolfson Medical Center · starts Dec 1, 2025
Approved 7
- Enoxaparin sodiumAntithrombin-III activator
- RivaroxabanCoagulation factor X inhibitor
- ApixabanCoagulation factor X inhibitor
- Dabigatran etexilateThrombin inhibitor
- Dalteparin sodiumAntithrombin-III activator
- EdoxabanCoagulation factor X inhibitor
- BetrixabanCoagulation factor X inhibitor
Phase 3 10
- Semuloparin sodiumAntithrombin-III inhibitor
- DarexabanCoagulation factor X inhibitor
- AspirinCyclooxygenase inhibitor
- WarfarinVitamin k epoxide reductase complex subunit 1 isoform 1 inhibitor
- HeparinAntithrombin-III activator
- FondaparinuxAntithrombin-III activator
- DabigatranThrombin inhibitor
- AbelacimabCoagulation factor XI inhibitor
- Nadroparin calciumAntithrombin-III activator
- Sulodexide
Phase 2 9
- ClopidogrelPurinergic receptor P2Y12 antagonist
- RosuvastatinHMG-CoA reductase inhibitor
- TirofibanIntegrin alpha-IIb/beta-3 inhibitor
- LetaxabanCoagulation factor X inhibitor
- TB-402Coagulation factor VIII inhibitor
- CiraparantagHeparin sequestering agent
- GW813893
- ANTI-PSGL-1 antibody SELK2
- SR-123781A
Phase 1 or earlier 5
- CyclosporineCyclophilin A modulator
- TacrolimusFK506-binding protein 1A inhibitor
- ClarithromycinBacterial 70S ribosome inhibitor
- ONO-7684
- AtorvastatinHMG-CoA reductase inhibitor
How its trials ended
636 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 164 whose ending is known, 51% met their primary endpoint, 8% missed it and 41% stopped early.
- Completed, result not reported27844%
- Ongoing12419%
- Met its primary endpoint8313%
- Status unknown7011%
- Stopped: other or unclear335%
- Stopped: enrollment or feasibility223%
- Missed its primary endpoint132%
- Stopped: sponsor or business decision51%
- Stopped: lack of efficacy41%
- Stopped: funding41%
| Aug 27, 2024 | The partum (postpartum aspirin to reduce thromboembolism undue morbidity) trialAcetylsalicylic acid | Governors of The University of Calgary | Ongoing |
| Jul 29, 2024 | Tranexamic acid to decrease heavy menstrual bleeding in individuals anticoagulated for venous thromboembolism (t-rex hmb) pilot studyTranexamic acid | University Health Network | Pending |
| May 8, 2024 | A master protocol for a phase 2 randomized, double-blind, placebo-controlled study of REGN9933 and REGN7508, monoclonal antibodies against factor xi for…REGN9933 / REGN7508 | Regeneron | Closed |
| May 3, 2024 | Reducing gastrointestinal bleeding with proton pump inhibitor therapy in acute venous thromboembolism: pilot randomized trial (radiant trial)Omeprazole | Ottawa Hospital Research Institute | Ongoing |
| Dec 2, 2022 | A phase 2, multicenter, randomized, open-label, active-control study of REGN9933, a factor xi monoclonal antibody, for prevention of venous thromboembolism…REGN9933 | Regeneron | Ongoing |
| Jan 7, 2022 | A multicenter, randomized, open-label, blinded endpoint evaluation, phase 3 study comparing the effect of abelacimab relative to apixaban on venous pixaban on…Abelacimab | Anthos Therapeutics, Inc. | Ongoing |
| Oct 29, 2021 | Treatment of cvd with lose dose rivaroxaban in advanced CKD (TRACK)Rivaroxaban | The George Institute for Global Health | Closed |
| Oct 21, 2021 | Primary thromboprophylaxis in patients with malignancy and central venous catheters: a randomized controlled trial (trim-line)Rivaroxaban | Ottawa Hospital Research Institute | Ongoing |
| Dec 3, 2020 | Towards improved adherence with extended vte prophylaxis after abdominal or pelvic major cancer surgeryApixaban | Hamilton Health Sciences Corporation | Closed |
| Jul 28, 2020 | The saver trial: statins for venous event reduction in patients with venous thromboembolismRosuvastatin | Ottawa Hospital Research Institute | Ongoing |
| Nov 21, 2025 | Svariya (previously Rivaroxaban Koanaa)Rivaroxaban · generic | PGF Pharma International d.o.o. | EMA ↗ |
| Feb 19, 2024 | Dabigatran etexilate Teva (previously Dabigatran etexilate Leon Farma)Dabigatran etexilate · generic | Teva GmbH | EMA ↗ |
| May 26, 2023 | Dabigatran Etexilate AccordDabigatran etexilate · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Nov 12, 2021 | Rivaroxaban Viatris (previously Rivaroxaban Mylan)Rivaroxaban · generic | Viatris Limited | EMA ↗ |
| May 19, 2021 | LydisilkaEstetrol; drospirenone | Estetra SPRL | EMA ↗ |
| Nov 16, 2020 | Rivaroxaban AccordRivaroxaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Jul 23, 2020 | Apixaban AccordApixaban · generic | Accord Healthcare S.L.U. | EMA ↗ |
| Sep 15, 2016 | InhixaEnoxaparin sodium · biosimilar | Techdow Pharma Netherlands B.V. | EMA ↗ |
| May 18, 2011 | EliquisApixaban | Bristol-Myers Squibb / Pfizer EEIG | EMA ↗ |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA